Team:Imperial College London/Project Overview
From 2009.igem.org
(→Motivation) |
(→Project Overview) |
||
Line 37: | Line 37: | ||
--> | --> | ||
- | = | + | =Our Solution= |
<b><i>The E.ncapsulator</i></b> is a novel protein manufacture and delivery platform designed to overcome these difficulties. In order to learn more about each module of the system and what its doing, hover over the different parts of the image below: | <b><i>The E.ncapsulator</i></b> is a novel protein manufacture and delivery platform designed to overcome these difficulties. In order to learn more about each module of the system and what its doing, hover over the different parts of the image below: | ||
<html> | <html> |
Revision as of 17:31, 18 October 2009
Contents |
Problem
The inspiration behind The E.ncapsulator was the inherent difficulty in delivering protein pharmaceuticals to the gut. Due to the delicate nature of proteins and the highly acidic environment present in the stomach, protein molecules are readily broken down - making oral drug delivery of protein pharmaceuticals impossible.
Some general statistics
There are several diseases that are treated using oral delivery of peptides. Among these are: Diabetes Mellitus and Phenylketonuria (PKU), a disease associated with mental retardation due to insufficient ability to metabolize phenylalanine.
- PKU (statistics from [1]):
- 1 per 10,000 - 15,000 newborns are diagnosed with phenylketonuria in the USA
- Prevalance Rate: approx 1 in 10,000 or 0.01% or 27,200 people in USA
- Diabetes Mellitus (statistics from [2]):
- 17,000,000 U.S. adults have physician-diagnosed diabetes (about 7.5 million males and 9.5 million females).
- 1,600,000 new cases of diagnosed diabetes are diagnosed every year.
Our Solution
The E.ncapsulator is a novel protein manufacture and delivery platform designed to overcome these difficulties. In order to learn more about each module of the system and what its doing, hover over the different parts of the image below:
Major Results
Achievements